Articles tagged with Schizophrenia
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
A new Northwestern University study has discovered a novel biomarker of schizophrenia that could also serve as a new drug candidate to treat the cognitive symptoms of the disorder. The study found that levels of the protein Cacna2d1 signal are reduced in patients with schizophrenia, resulting in overactive brain circuits.
Early alterations in the brain's clearance system may contribute to psychosis vulnerability. A study found that individuals with 22q11.2 deletion syndrome, a genetic condition, had impaired glymphatic system function from childhood, which may promote psychosis onset.
Emerging research across conceptual frameworks, biomarker science, digital phenotyping, and artificial intelligence synthesizes a translational pathway toward a more biologically grounded and clinically useful approach to psychiatric diagnosis. The current system falls short due to standardized clinical language and lack of biological ...
A study of over 1 million diagnosed individuals reveals genetic links between 14 psychiatric conditions, grouping them into five major factors. The findings may facilitate future treatments and drug repurposing, with potential applications in schizophrenia and substance abuse
A massive Swedish study of over 2 million individuals reveals that genetic risk for mental illness is far less disorder-specific than clinicians have assumed. Schizophrenia shows the highest genetic specificity, while drug use disorder has a much lower specificity, scattering its genetic risk across multiple conditions.
Researchers review schizophrenia mechanisms, including neurotransmitter dysregulation and immune dysfunction, to develop next-generation therapies. Promising treatments include TAAR1 agonists, muscarinic modulators, NMDA receptor enhancers, and probiotics targeting the gut-brain axis.
The study reveals that psychosis does not follow a single trajectory but is influenced by individual differences and treatment. It shows that cortical volume reduction, particularly in regions with high serotonin and dopamine receptor density, is a hallmark of the disease.
Researchers found that brexpiprazole significantly improved information processing speed without worsening psychiatric symptoms in patients with schizophrenia. Cognitive dysfunction is a persistent challenge, affecting daily functioning and social participation.
A rare genetic mutation has been discovered that can explain why some people do not respond to newer schizophrenia treatments. The mutation, known as C182F, removes a structural bond in the TAAR1 receptor, blocking its binding site and rendering drugs ineffective.
A large study of over 12 million people in Ontario found that psychosis rates are increasing in more recent generations, with higher rates among younger individuals. The study suggests that factors such as substance use, socioeconomic stress, and negative childhood experiences may contribute to these rising trends.
Research suggests that lower oral microbiota diversity is associated with poorer cognitive function in people with schizophrenia. The study also identified specific microbial metabolic pathways potentially linked to this relationship.
A landmark study has identified over 100 ancestry-independent regions of the genome that influence schizophrenia risk in African Americans and other ancestrally diverse populations. The findings address a long-standing gap in psychiatric genetics and offer a more inclusive view of the disease’s biological underpinnings.
A recent study published in Nature identified over 100 new genetic regions linked to schizophrenia that had not been previously discovered. These findings show that while specific genetic variants may differ across populations, the core biological mechanisms underlying schizophrenia are shared worldwide.
Researchers discovered a crucial role of alternative RNA splicing in schizophrenia by identifying genetic variants affecting splicing and protein isoforms. The study highlights the significance of unannotated isoforms in disease pathogenesis and suggests potential avenues for targeted therapeutic strategies.
Researchers from Kyushu University found that the brain forms new, high-density clusters of synapses on specific segments of dendrites during adolescence, challenging the 'adolescent synaptic pruning' hypothesis. This discovery may offer new hope for understanding the biological basis of schizophrenia and other neurodevelopmental condi...
Researchers discovered the cerebellum's key role in regulating the brain's reward system in people with schizophrenia. Stronger cerebellar regulation is associated with reduced negative symptoms, while weaker regulation increases symptoms. This finding opens up new avenues for targeted therapeutic interventions.
Research from Karolinska Institutet found that alpha frequency determines body ownership by modulating temporal integration of bodily signals. Faster frequencies led to higher temporal resolution, while slower frequencies caused broader timing differences.
A comprehensive genetic investigation by Dr. Feng Liu and collaborators identifies shared genetic loci between schizophrenia and osteoporosis, suggesting overlapping biological pathways. The study found that psychiatric patients face elevated fracture risks due to these molecular connections.
Researchers at Flinders University discover a genetic mutation that silences a brain receptor, rendering it unresponsive to both natural trace amines and clinical drug candidates. The C182F variant eliminates receptor signaling and reduces cell surface expression, with profound implications for emerging psychiatric treatments.
Scientists at Lund University have created a new method to directly reprogram glial cells into parvalbumin neurons, which can help regulate brain activity and potentially treat disorders such as schizophrenia and epilepsy. The breakthrough could lead to therapies that replace lost or damaged brain cells in the future.
A new study reveals limited data on cognition in individuals with comorbid personality disorder and schizophrenia, leading to unfavourable outcomes. The researchers emphasize the need for further investigation into adapting treatments to support functional recovery.
A randomized clinical trial shows that semaglutide improves glycemic control and weight outcomes in individuals with schizophrenia. The study suggests using glucagon-like peptide-1 receptor agonists as an early intervention strategy to reduce cardiometabolic risk in this population.
A study from the University of Seville found that patients with schizophrenia spectrum disorders show significant reductions in structural similarity between different brain regions, particularly in the temporal, cingulate, and insular lobes. These alterations are associated with cognitive deficits and severe symptoms.
Researchers identified distinct epigenetic signatures in cord blood linked to increased schizophrenia and other neurodevelopmental conditions. Newborns with higher genetic susceptibility showed differences in DNA methylation patterns, especially in immune-related regions.
Researchers identified patterns that could help match the right treatment to the right patient by tracking real-world responses. Patients with prominent negative symptoms showed strongest improvements after receiving the new combination drug, while those with aggression or bipolar features saw limited benefit. The study suggests schizo...
Researchers discover tiny antibody-like proteins from camels and llamas that can treat brain disorders like schizophrenia and Alzheimer’s disease with fewer side effects. The nanobodies are smaller than conventional antibodies, making them easier to produce and purify.
A recent study has found that auditory verbal hallucinations in schizophrenia may stem from a disruption in the brain's ability to recognize its own inner voice. Researchers used EEG to measure brainwaves as participants listened to audio and imagined speaking, revealing a stronger reaction in people with schizophrenia who heard voices.
Researchers developed a machine learning model that uses MRI scans to predict which patients with mental illnesses will gain weight after diagnosis, and which ones won't. The BMIgap tool has the potential to prevent future weight gain and reduce the risk of metabolic diseases.
Groundbreaking research by Dr. Bruce M. Cohen has uncovered critical abnormalities in energy metabolism and cellular connectivity that contribute to psychiatric disorders. The study's findings suggest therapeutic avenues that may be better targeted and more effective than current treatments.
Researchers from the University of South Australia explore the connection between the gut and brain to decipher their role in mental health and wellbeing. The study found that changes in the gut microbiome can directly affect brain chemistry, suggesting a potential link between gut health and mental illness.
Researchers identify abnormal sugar modifications linked to depressive behaviors, offering potential diagnostic and therapeutic targets. Chronic stress disrupts sugar chains in the prefrontal cortex, triggering depression.
A major review of international evidence found that racial discrimination contributes to the development of psychosis, with people experiencing discrimination being 77% more likely to develop psychotic symptoms. The study highlights the need for public health action to tackle systemic racism and its impact on mental health disparities.
A study has created a detailed temporal map of epigenetic changes in the human brain from six weeks after conception to 108 years of age. This reveals that genes linked to autism and schizophrenia undergo dynamic DNA methylation changes during development, highlighting their role in brain cortex formation.
Researchers manipulated the endocannabinoid signaling system in prenatal mice, leading to altered gene expression, neural properties, and social interaction deficits. This work suggests that prenatal manipulation of this system may lead to neuropsychiatric conditions, particularly those involving social deficits.
Johns Hopkins researchers used machine learning to analyze electric activity of mini-brains grown in a lab, revealing unique firing patterns associated with schizophrenia and bipolar disorder. The study improves accuracy in distinguishing between healthy and unhealthy brain organoids, paving the way for potential diagnostic tests and p...
The study found sex differences in age at diagnosis, treatment onset, illness duration, illicit drug use, and smoking among individuals with bipolar disorder and schizophrenia. Females showed better functioning and neurocognitive performance than males, while males had higher rates of substance use.
Researchers created a comprehensive brain-wide activity map of decision-making in mice, revealing that signals are distributed across multiple brain regions. The study challenges traditional hierarchical views and highlights the importance of prior expectations in guiding behavior.
People with schizophrenia are more likely to develop chronic obstructive pulmonary disease (COPD) due to shared genetic, socioeconomic, and environmental factors. The lack of adequate medical care also contributes to the under-diagnosis of COPD in this population.
Newron Pharmaceuticals' evenamide has been shown to target the key site of schizophrenia pathology in the hippocampus, improving positive, negative, and cognitive symptoms. The study's findings suggest that evenamide could offer a novel therapeutic strategy capable of addressing schizophrenia-related dysfunction.
Dr. Camilo de la Fuente-Sandoval has developed a groundbreaking approach to schizophrenia treatment prediction using neuroimaging and comprehensive clinical care. His team's research reveals elevated glutamate levels in the associative striatum that normalize with effective antipsychotic treatment.
Researchers at the Institute for Basic Science have discovered that excessive GABA produced by astrocytes impairs fear extinction in PTSD. A new brain-permeable drug called KDS2010 has reversed PTSD-like symptoms in mice, providing a promising therapeutic approach.
Researchers used IntelliCage to assess spontaneous behavioral changes in a mouse model of schizophrenia, finding increased hyperactivity and exploratory behavior after treatment with MK-801. However, cognitive flexibility was impaired, suggesting schizophrenia-like behaviors.
Scientists have designed a nanobody made from llama antibodies to activate a glutamate receptor involved in neural activity, improving cognitive function in mouse models of schizophrenia. Peripheral administration has shown promise as a new therapeutic strategy for treating the condition.
Researchers from Drexel University's A.J. Drexel Autism Institute examined hospitalizations for mental health conditions in autistic adults and found that nearly 1.5 times more autistic adults were readmitted to the hospital within 30 days of initial discharge compared to non-autistic adults.
Dr. Deanna L. Kelly has been named Director of the Maryland Psychiatric Research Center, building on her expertise in schizophrenia treatments and nutrition. She continues to advance personalized treatment options, including effective medications and innovative dietary interventions.
A new research paper introduces DoliClock, a biological aging clock based on lipid profiles in the human brain, showing accelerated brain aging in individuals with autism, schizophrenia, and Down syndrome. The study found that dolichol levels serve as reliable biomarkers of aging.
A Nagoya University group created a sandwich ELISA technique to accurately measure polysialic acid levels in the blood of patients with psychiatric disorders. The technique uses antibodies that minimize non-specific binding, resulting in increased accuracy.
The Lieber Institute is developing a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as schizophrenia. The institute is utilizing AWS gen AI and compute services to advance research and store its massive collection of genomic and other data in the cloud.
Researchers have developed a once-a-week pill that can be taken orally to deliver medication to patients with schizophrenia. The treatment maintains consistent levels of the drug in the body and controls symptoms, making it easier for patients to adhere to their medication regimen.
A new study found that taking antipsychotic medication as prescribed significantly reduces the odds of a motor vehicle crash among drivers with schizophrenia. Researchers analyzed 20 years of data and found a 50% reduction in crash risk among those who adhered to their medication.
A new study published in Neuron has identified a brain region, the fusiform gyrus, as key to distinguishing between real and imagined experiences. The region's strength of activity can predict whether someone judges an experience as real or imagined.
A new study shows that lowering EMC10 levels restores brain function and memory in models of 22q11.2 Deletion Syndrome. Reducing EMC10 activity also alleviates symptoms, including improved cognitive deficits and social memory performance.
A new study finds that Medicaid unwinding disrupted kids' and young adults' access to chronic disease medication, particularly for those living in states with the largest drops in Medicaid enrollment. The disruptions led to increased use of private insurance or cash for prescriptions, exacerbating health issues.
A recent study by the University of Zurich examined the connection between retinal nerve connections and schizophrenia. The researchers found that individuals with a higher genetic risk for schizophrenia tend to have thinner retinas, which can be detected using non-invasive retinal measurements.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.
A nationwide Finnish register-based cohort study found that young people with mental disorders are less likely to become parents compared to those without such diagnoses. The strongest associations were for schizophrenia and depression, with men being 38% less likely to become fathers due to depression diagnosis.
University of California researchers developed a new drug, JRT, with reduced hallucinogenic potential compared to LSD. The compound has shown promise in treating the negative and cognitive symptoms of schizophrenia, including anhedonia and cognitive function.
Researchers have found that puberty triggers significant changes in brain connectivity patterns in individuals with a rare genetic disorder tied to autism. The study suggests that synaptic dysfunction during development may contribute to the condition's behavioral challenges.
Dr. Romina Mizrahi's PET-based neuroimaging sheds light on brain workings, integrating genetics, environment and imaging to understand psychiatric illness as a complex biological puzzle. She advocates for precision psychiatry paradigm with customized treatments based on molecular profiles, and calls for diversity in academic leadership.